百濟神州
Beone MedicinesHKHKDBeone Medicines (US:BEIGF) — Biotechnology: Pharmaceutical Preparations. Number of exchanges where the company shares trade: 2. On this page — price and chart, dividends, top holders and share count history.
About the company
- Website
- beonemedicines.com
- Investor relations
- ir.beonemedicines.com/
- Sector
- Health Care · Biotechnology: Pharmaceutical Preparations
- Headquarters
- BASEL, Switzerland
- Management
- Latest reports
- Employees
- 12 000
- Founded
- 2010
- IPO
- 2016-03-02
- Shares outstanding
- Free float
- 1.05 B
- Market cap
- 348.24 B HKD
- Insiders
- 13.75%
- Institutions
- 28.85%
- Industry (SIC)
- Pharmaceutical Preparations
- ISIN
- CH1391448177
- P/EP/E (Price / Earnings) — how many years of the company's profit you pay for a share. Calculated: current price ÷ net earnings per share over the last 12 months. Lower means cheaper relative to profit. Not calculated when the company has a loss (—).
- 51.0
- EPSEPS (Earnings Per Share) — the company's net profit over the last 12 months divided by the number of its shares, in the currency of this listing. A negative value (red) means a loss. P/E is the share price divided by EPS.
- 0.43 USD
- |P/B (price to book) — share price ÷ shareholders' equity per share from the latest balance sheet. Graham — as Benjamin Graham counted it: equity without goodwill, other intangible assets and preferred stock, that is tangible book value. He considered up to 1.5 acceptable for a defensive investor (green), or a product P/E × P/B up to 22.5. With negative tangible equity, Graham's P/B is not calculated.
- 7.937.98
- Graham numberGraham number — the highest price Benjamin Graham considered reasonable for a defensive investor: √(22.5 × EPS × tangible book value per share), where 22.5 = P/E 15 × P/B 1.5. A price below it (green) passes both of his limits at once. Not calculated with a loss or negative tangible equity.
- 5.16 USD price 325% above
- FCFFCF (Free Cash Flow) — money left to the company after operating costs and investment in equipment; dividends are safest when paid from it. Calculated: operating cash flow − capital expenditure, over the last 12 months, in the reporting currency.
- 1.45 B USD
- DebtDebt — all loans and bonds of the company per the latest report (short- and long-term), in the reporting currency. Below — how many years the company would need to repay net debt (debt minus cash) from its free cash flow: net debt ÷ FCF. Up to 3 years — good, 3–6 — moderate, over 6 — high. «Net cash» — net debt is negative.
- 866 M USDnet cash
- Earnings and FCF — for the 12 months to 30.09.2026 (the company's latest report).
- Net income
- NAVNAV — net asset value by the balance sheet: the company's assets minus its liabilities, the share of the company's shareholders (without other owners' stakes in its subsidiaries). Shown per share, with P/NAV — how many times the share price exceeds NAV per share (below 1 — the share costs less than its net assets on the balance sheet). Click to see what NAV is made of and its history.
Description
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. The company has a agreement with U.S. government to expand access to innovative cancer medicines. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
Top holders
| Holder | Stake | Shares | Report date |
|---|---|---|---|
| Oyler (John Victor) (Chi… | ≈1.73% | 24.73 M | 2025-12-31 |
| VANGUARD STAR FUNDS-Vang… | 0.84% | 11.98 M | 2026-07-31 |
| VANGUARD Intl Eqy. INDEX… | 0.79% | 11.31 M | 2026-07-31 |
| iShares, Inc.-iShares Co… | 0.64% | 9.16 M | 2026-08-31 |
| Wang (Xiaodong) (Directo… | ≈0.37% | 5.36 M | 2025-12-31 |
| HARTFORD MUTUAL Fd.S II… | 0.21% | 2.99 M | 2026-07-31 |
| NEW PERSPECTIVE FUND | 0.2% | 2.87 M | 2026-06-30 |
| Baillie Gifford Funds-Ba… | 0.2% | 2.85 M | 2026-06-30 |
| iShares Trust-iShares Ch… | 0.2% | 2.84 M | 2026-08-31 |
| New World Fund Inc | 0.2% | 2.83 M | 2026-07-31 |
| iShares, Inc.-iShares MS… | 0.14% | 2.02 M | 2026-08-31 |
| iShares Trust-iShares MS… | 0.14% | 1.98 M | 2026-08-31 |
| Goller (Michael J.) (Ind… | ≈0% | 63 037 | 2025-12-31 |
| Krishana (Ranjeev) (Inde… | ≈0% | 63 037 | 2025-12-31 |
| Sanders (Corazon Corsee… | ≈0% | 46 241 | 2025-12-31 |
| Dugan (Margaret) (Indepe… | ≈0% | 45 955 | 2025-12-31 |
| Riva (Alessandro) (Indep… | ≈0% | 45 955 | 2025-12-31 |
| Hooper (Anthony C) (Inde… | ≈0% | 37 414 | 2025-12-31 |
| BRANDICOURT OLIVIER (Ind… | ≈0% | 16 341 | 2025-12-31 |
| Yi (Qingqing) (Independe… | ≈0% | 16 341 | 2025-12-31 |
| Generali Investments, Ma… | 0% | 8 000 | 2025-12-31 |
Sign in with Google